SEC Form 4 · accession 0000891293-18-000059
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam R Craig
Officer — President and CEO · Director
Period of report
May 16, 2018
Accepted (ET)
May 17, 2018 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $4.14 | May 16, 2018 | A | 475,000 | A | — | May 16, 2028 | Common Stock | 475,000 | 475,000 | D |
Explanation of responses
- F1The stock option will vest in six equal semi-annual installments over a three-year period commencing on March 9, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on March 9, 2021.